Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 28 August 2019, 09:58 HKT/SGT
Share:
    

Source: Eisai
Eisai Enters Into Business Alliance With Cogstate for Exclusive Development and Commercialization of a Digital Tool for Self-Assessment of Cognitive Function in Japan

TOKYO, Aug 28, 2019 - (JCN Newswire) - Eisai Co., Ltd. has entered into a business alliance agreement for exclusive development and commercialization of a cognitive function test - Cogstate Brief Battery (CBB) - developed by Cogstate Ltd., in Japan as a digital tool for self-assessment of cognitive function (classified as miscellaneous goods).

The CBB consists of four tests, each measuring different cognitive domains: psychomotor function, attention, working memory, and learning, and it has been developed and already in use as a digital tool for self-assessment of cognitive function overseas, including the United States.

Eisai will aim to raise awareness of cognitive function by developing and making widely available the CBB in Japan jointly with Cogstate as a simpler digital tool for self-assessment of cognitive function, which can be used at various locations such as at home and community events. With this tool, it is expected to have opportunities to review lifestyle and to consult with specialists and primary care physicians by objectively checking the changes in cognitive function. It is important to note that this tool is not an alternative for medical examination and diagnosis by qualified medical professionals.

In its medium-term business plan, EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), promoting various kinds of digitalization such as the analysis of big data, including using real world data to develop an environment for early diagnosis and initiation of treatment and provision of solutions. This also includes creating next-generation treatments primarily in "neurology" and "oncology" that are Eisai's therapeutic areas of focus. Through these efforts to partner with Cogstate to develop and make widely available the CBB as a digital tool for self-assessment of cognition more easily in Japan where aging is progressing and to raise awareness of cognitive function, Eisai aims to contribute to the realization of well-being.

About Cogstate Ltd.

Cogstate Ltd. (ASX:CGS) is a neuroscience technology company headquartered in Melbourne, Victoria, Australia, optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare since 1999. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For nearly 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. For more information, please visit www.cogstate.com.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Aug 28, 2019 09:58 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 5, 2019 09:02 HKT/SGT
Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
Oct 23, 2019 10:13 HKT/SGT
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 15, 2019 20:24 HKT/SGT
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
Oct 1, 2019 10:46 HKT/SGT
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
Sept 30, 2019 11:06 HKT/SGT
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
Sept 26, 2019 13:21 HKT/SGT
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
Sept 26, 2019 13:08 HKT/SGT
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
Sept 24, 2019 09:01 HKT/SGT
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress
Sept 20, 2019 15:13 HKT/SGT
Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan
Sept 20, 2019 08:40 HKT/SGT
Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: